RAS Mutation in Mucinous Carcinoma of the Ovary

Document Type: Research Articles

Authors

1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital Bangkok, Thailand.

2 Chulalongkorn GenePRO Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

3 Division of Cyto-pathology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Abstract

Objective: This study was designed to identify genetic mutation in mucinous carcinoma of the ovary of the patients
in King Chulalongkorn Memorial hospital, Bangkok, Thailand and study the relationship between genetic mutation
and patients’ prognosis. Methods: Fifty cases of primary mucinous carcinoma of the ovary were selected. DNA was
analyzed for genetic mutation using ColoCarta Panel v1.0 and MassArray® System. Demographic data and clinical
information of the participants were reviewed from electronic medical records and government data services. Results:
Median of disease-free survival is 171.33 +/- 9.04 months and the median overall survival is 171.37 +/- 9.03 months.
Twelve percent of the participants had recurrence and all of recurrent cases died from disease or its complication. We
found three mutations which were KRAS (27 cases, 54%), PIK3CA (4 cases, 8%) and BRAF (1 case, 2%). Among the
KRAS-mutated patients, the majority of the cases (25 cases, 92.6%) were in stage I. Recurrence and disease related
mortality were not observed in the KRAS mutated patients. Conclusion: The genetic mutation analysis found three
mutations which were KRAS 27 cases (54%), PIK3CA 4 cases (8%) and BRAF 1 case (2%) The ovarian mucinous
carcinoma patients with KRAS mutation in our study showed excellent prognosis.

Keywords

Main Subjects